Featured Research

from universities, journals, and other organizations

Disputed asthma drugs have safe record in British Columbia

Date:
November 26, 2013
Source:
University of British Columbia
Summary:
A popular combination asthma therapy dogged by safety concerns has not harmed British Columbians and should remain in use, according to researchers. The study found no significant difference in hospitalization rates for patients who took inhaled corticosteroids alone and those who used the combination therapy.

A popular combination asthma therapy dogged by safety concerns has not harmed British Columbians and should remain in use, according to researchers at the University of British Columbia and Vancouver Coastal Health Research Institute.

The therapy combines an inhaled corticosteroid to reduce swelling in the airways with "long-acting beta agonists" (LABAs) to ease breathing and reduce the risk of a severe asthma attack. The U.S. Food and Drug Administration (FDA), reacting to claims that LABAs might mask conditions that leave patients vulnerable to more severe or even fatal asthma attacks, ordered the drugs' makers to conduct large-scale safety trials; with results not expected for five years, the FDA urges that LABAs be discontinued once a person's asthma is under control.

The UBC-Vancouver Coastal Health study examined hospitalization rates for patients who took inhaled corticosteroids alone and those who used the combination therapy, covering 46,000 people over 15 years. Although the hospitalization rate for combination therapy users was 14 per cent higher than those who took corticosteroids alone, that difference was not statistically significant.

"By including so many patients and over such a long period, we have provided unparalleled evidence on the safety of the combination therapy," said lead author Mohsen Sadatsafavi, an assistant professor of health economics in the Division of Respiratory Medicine and a scientist at the Centre for Clinical Epidemiology and Evaluation. "Our findings should reassure patients, doctors and policy-makers about the safety of combination therapies as we wait for the results of the trials."

This study should prompt a re-examination of the FDA's warning to restrict the use of combination therapy, said senior author Dr. Mark FitzGerald, Head of the Division of Respiratory Medicine of UBC and Vancouver General Hospital. "Patients who get relief from the combination therapy should continue using it without fear," he said.

Although corticosteroids and LABAs can be taken as two separate inhalers, most patients use a version that includes both drugs in one dose. Advair, made by GlaxoSmithKline PLC, is the fourth-highest selling drug in the world, with 2012 global sales of $4.6 billion (U.S.). Another combination therapy, Symbicort, made by AstraZeneca Pharmaceuticals, had 2012 global sales of $1.2 billion (U.S.). Merck & Co. has also introduced its own formulation, Zenhale.

The study confirmed that LABAs, when used without inhaled corticosteroids, do indeed pose a risk. Patients who used LABAs exclusively had an 86 per cent increased rate of hospitalization compared to those who didn't use anything at all. However, the risk of hospitalization decreased in direct proportion to the increased use of corticosteroids.


Story Source:

The above story is based on materials provided by University of British Columbia. Note: Materials may be edited for content and length.


Cite This Page:

University of British Columbia. "Disputed asthma drugs have safe record in British Columbia." ScienceDaily. ScienceDaily, 26 November 2013. <www.sciencedaily.com/releases/2013/11/131126191630.htm>.
University of British Columbia. (2013, November 26). Disputed asthma drugs have safe record in British Columbia. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2013/11/131126191630.htm
University of British Columbia. "Disputed asthma drugs have safe record in British Columbia." ScienceDaily. www.sciencedaily.com/releases/2013/11/131126191630.htm (accessed July 25, 2014).

Share This




More Health & Medicine News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

AFP (July 24, 2014) A so-called drugs rehab 'clinic' is closed down in Pakistan after police find scores of ‘patients’ chained up alleging serial abuse. Duration 03:05 Video provided by AFP
Powered by NewsLook.com
Too Few Teens Receiving HPV Vaccination, CDC Says

Too Few Teens Receiving HPV Vaccination, CDC Says

Newsy (July 24, 2014) The Centers for Disease Control and Prevention is blaming doctors for the low number of children being vaccinated for HPV. Video provided by Newsy
Powered by NewsLook.com
New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile: iPhone Android Web
          Follow: Facebook Twitter Google+
          Subscribe: RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins